Fulgent Genetics Expands Diagnostic Footprint with $56.9M Dual Acquisition
Event summary
- Fulgent Genetics completed the acquisition of Bako Diagnostics and StrataDx for $56.9M in cash, finalizing a deal announced December 22, 2025.
- Bako Diagnostics provides specialty pathology services, while StrataDx focuses on dermatopathology diagnostics.
- The acquisition expands Fulgent's diagnostic capabilities beyond its core genetic testing business.
- Fulgent aims to integrate these assets into its precision medicine strategy.
The big picture
Fulgent's acquisition of Bako Diagnostics and StrataDx represents a strategic pivot toward broadening its diagnostic capabilities, complementing its existing genetic testing business. This move aligns with the broader industry trend of consolidating diagnostic services to create more comprehensive precision medicine platforms. The $56.9M deal underscores Fulgent's commitment to scaling beyond its core offerings, though success will hinge on seamless integration and effective monetization of the expanded service portfolio.
What we're watching
- Integration Challenges
- How Fulgent will manage the operational and cultural integration of two distinct diagnostic labs into its existing structure.
- Market Adoption
- Whether the expanded diagnostic menu will accelerate Fulgent's transition into a fully integrated precision medicine company.
- Reimbursement Dynamics
- The pace at which Fulgent can secure coverage and adequate reimbursement for the acquired labs' specialized testing services.
Related topics